CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company’s leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Metrics to compare | CYDY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCYDYPeersSector | |
---|---|---|---|---|
P/E Ratio | 142.7x | −4.5x | −0.5x | |
PEG Ratio | 1.40 | 0.02 | 0.00 | |
Price/Book | −3.4x | 2.7x | 2.6x | |
Price / LTM Sales | - | 150.6x | 3.3x | |
Upside (Analyst Target) | - | 187.1% | 43.5% | |
Fair Value Upside | Unlock | 3.5% | 6.8% | Unlock |